Company profile
Valneva SE
NASDAQ:VALNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| JAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED) | phase3 | — | 8 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (38)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06028841 | phase3 | withdrawn | 2024-04-10 | 2024-08-27 | Valneva Austria GmbH | A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) |
| NCT06106581 | phase2 | completed | 2023-12-18 | 2024-07-31 | Valneva Austria GmbH | A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years |
| NCT07133178 | phase3 | withdrawn | 2026-02-06 | 2026-12-01 | Valneva Austria GmbH | A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children |
| NCT01296386 | phase1 | completed | 2010-12-01 | 2013-04-01 | Valneva Austria GmbH | An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 |
| NCT04838444 | phase3 | active_not_recruiting | 2021-04-02 | 2023-03-03 | Valneva Austria GmbH | Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125280 | BLA | Valneva Austria GmbH | ||||
Loading… | ||||||
| BLA 125777 | BLA | Valneva Austria GmbH | ||||
Loading… | ||||||